Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Clin Transl Oncol ; 14(5): 338-49, 2012 May.
Article in English | MEDLINE | ID: mdl-22551539

ABSTRACT

Patients with advanced non-small-cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) mutations can now have specific treatment based on the result of biomarker analysis and patients with rearrangements of the anaplastic lymphoma kinase (ALK) gene will probably soon be able to. This will give them better quality of life and progression-free survival than conventional chemotherapy. This consensus statement was conceived as a joint initiative of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP), and makes diagnostic and treatment recommendations for advanced NSCLC patients based on the scientific evidence on biomarker use. It therefore provides an opportunity to improve healthcare efficiency and resource use, which will undoubtedly benefit these patients. Although this field is in continuous evolution, at present, with the available data, this panel of experts recommends that all patients with advanced NSCLC of non-squamous cell subtype, or non-smokers regardless of the histological subtype, should be tested for EGFR gene mutations within a maximum of 7 days from the pathological diagnosis. Involved laboratories must participate in external quality control programmes. In contrast, ALK gene rearrangements should only be tested in the context of a clinical trial, although the promising data obtained will certainly justify in the near future its routine testing in patients with no EGFR mutations. Lastly, routine testing for other molecular abnormalities is not considered necessary in the current clinical practice.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Carcinoma, Non-Small-Cell Lung/genetics , Consensus , Humans , Lung Neoplasms/genetics , Medical Oncology , Societies, Medical , Spain
2.
Clin Transl Oncol ; 13(9): 636-51, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21865135

ABSTRACT

The identification of HER2 alterations in advanced gastric carcinomas is of critical importance in daily clinical practice as such neoplasms require specific treatment with trastuzumab. For these reasons, pathologists and oncologists with expertise in gastric carcinomas and HER2 testing from both organisations (SEAP and SEOM) have endeavoured to discuss and agree on national guidelines for HER2 testing in gastric carcinomas. These guidelines are based on the experience of those who participated in the discussions and also on experience published internationally. These agreed guidelines give the minimum requirements that a pathological anatomy laboratory must fulfil in order to guarantee adequate HER2 testing in daily practice. Any laboratories which do not meet the minimum standards set out in the guidelines must make every effort to achieve compliance.


Subject(s)
Carcinoma/genetics , Consensus , Genes, erbB-2 , Genetic Testing/methods , Genetic Testing/statistics & numerical data , Stomach Neoplasms/genetics , Algorithms , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Carcinoma/diagnosis , Carcinoma/pathology , Clinical Laboratory Techniques/methods , Clinical Trials as Topic , Genes, erbB-2/genetics , Humans , Medical Oncology/legislation & jurisprudence , Medical Oncology/methods , Medical Oncology/organization & administration , Pathology, Molecular/legislation & jurisprudence , Pathology, Molecular/methods , Pathology, Molecular/organization & administration , Practice Guidelines as Topic , Societies, Medical/legislation & jurisprudence , Spain , Stomach Neoplasms/diagnosis , Stomach Neoplasms/pathology
3.
Clin Transl Oncol ; 11(6): 363-75, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19531451

ABSTRACT

Identifying breast cancers with HER2 overexpression or amplification is critical as these usually imply the use of HER2-targeted therapies. DNA (amplification) and protein (overexpression) HER2 abnormalities usually occur simultaneously and both in situ hybridisation and immunohistochemistry may be accurate methods for the evaluation of these abnormalities. However, recent studies, including those conducted by the Association for Quality Assurance of the Spanish Society of Pathology, as well as the experience of a number of HER2 testing National Reference Centres have suggested the existence of serious reproducibility issues with both techniques. To address this issue, a joint committee from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) was established to review the HER2 testing guidelines. Consensus recommendations are based not only on the panellists' experience, but also on previous consensus guidelines from several countries, including the USA, the UK and Canada. These guidelines include the minimal requirements that pathology departments should fulfil in order to guarantee proper HER2 testing in breast cancer. Pathology laboratories not fulfilling these standards should make an effort to meet them and, until then, are highly encouraged to submit to reference laboratories breast cancer samples for which HER2 determination has clinical implications for the patients.


Subject(s)
Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , DNA, Neoplasm/analysis , Genes, erbB-2 , Immunohistochemistry/methods , In Situ Hybridization/methods , Pathology Department, Hospital/standards , Specimen Handling/methods , Algorithms , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/pathology , Clinical Trials, Phase III as Topic/statistics & numerical data , Female , Forms and Records Control/standards , Humans , Immunohistochemistry/standards , In Situ Hybridization/standards , Multicenter Studies as Topic , Pathology Department, Hospital/organization & administration , Pathology Department, Hospital/statistics & numerical data , Quality Assurance, Health Care/organization & administration , Reagent Kits, Diagnostic , Reproducibility of Results , Spain , Specimen Handling/standards , Trastuzumab
SELECTION OF CITATIONS
SEARCH DETAIL